<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BrandRank Year-End Brand Snapshot - Ozempic</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica', Arial, sans-serif; color: #374151; background: white; line-height: 1.5; font-size: 10pt; }
        .page { max-width: 8.5in; margin: 0 auto; padding: 0.75in; background: white; min-height: 11in; }
        .header { display: flex; justify-content: space-between; align-items: center; padding-bottom: 12px; border-bottom: 2px solid #1a3a5c; margin-bottom: 24px; }
        .header-logo { font-weight: bold; color: #1a3a5c; font-size: 11pt; }
        .brand-logo { color: #6b7280; font-style: italic; font-size: 9pt; }
        .report-title { font-size: 22pt; font-weight: bold; color: #1a3a5c; text-transform: uppercase; letter-spacing: 2px; margin-bottom: 4px; }
        .report-subtitle { font-size: 14pt; font-weight: bold; color: #1a3a5c; margin-bottom: 20px; }
        .headline { font-size: 13pt; font-weight: bold; color: #1a3a5c; margin-bottom: 16px; line-height: 1.4; }
        .callout-box { background: #f8f9fa; border-left: 4px solid #1a3a5c; padding: 16px 20px; margin-bottom: 18px; }
        .callout-title { font-weight: bold; margin-bottom: 8px; color: #1a3a5c; }
        .callout-text { font-size: 10pt; line-height: 1.6; }
        .section { margin-bottom: 16px; }
        .section-header { font-size: 12pt; font-weight: bold; color: #1a3a5c; border-bottom: 2px solid transparent; background: linear-gradient(to right, #1a3a5c 0%, #2d5a82 100%) bottom / 100% 2px no-repeat; padding-bottom: 6px; margin-bottom: 10px; }
        .subsection-header { font-weight: bold; color: #374151; margin-top: 10px; margin-bottom: 6px; }
        .engine-breakdown { background: linear-gradient(135deg, #f1f5f9 0%, #f8f9fa 100%); padding: 20px; margin: 12px 0; text-align: center; border-radius: 4px; border: 1px solid #e5e7eb; }
        .engine-row { display: flex; justify-content: space-around; margin-bottom: 8px; font-size: 9pt; color: #6b7280; font-weight: 600; text-transform: uppercase; letter-spacing: 0.3px; }
        .engine-scores { display: flex; justify-content: space-around; font-weight: bold; font-size: 16pt; color: #1a3a5c; }
        .score-boxes { display: flex; gap: 12px; margin: 12px 0; }
        .score-box { flex: 1; background: linear-gradient(135deg, #f8f9fa 0%, #ffffff 100%); padding: 20px 16px; text-align: center; border-radius: 4px; box-shadow: 0 1px 3px rgba(0,0,0,0.1); border: 1px solid #e5e7eb; }
        .score-box-title { font-size: 10pt; font-weight: bold; color: #6b7280; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 0.5px; }
        .score-box-value { font-size: 24pt; font-weight: bold; color: #1a3a5c; }
        table { width: 100%; border-collapse: collapse; margin: 12px 0; font-size: 10pt; }
        th { background: #f3f4f6; padding: 10px 12px; text-align: left; font-weight: bold; color: #1a3a5c; border-bottom: 2px solid #1a3a5c; }
        td { padding: 10px 12px; border-bottom: 1px solid #e5e7eb; vertical-align: top; }
        tr:last-child td { border-bottom: none; }
        ul { margin-left: 20px; line-height: 1.6; }
        ul li { margin-bottom: 4px; }
        .button-container { margin: 16px 0; text-align: center; }
        .dashboard-button { display: inline-block; background: linear-gradient(135deg, #1a3a5c 0%, #2d5a82 100%); color: white; padding: 10px 24px; text-decoration: none; border-radius: 4px; font-weight: 600; font-size: 10pt; box-shadow: 0 2px 4px rgba(0,0,0,0.1); transition: all 0.2s; }
        .dashboard-button:hover { box-shadow: 0 4px 8px rgba(0,0,0,0.15); transform: translateY(-1px); }
        .footer { margin-top: 32px; padding-top: 12px; border-top: 1px solid #e5e7eb; text-align: center; font-size: 9pt; color: #6b7280; }
        .swot-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; margin: 12px 0; }
        .swot-box { background: #f8f9fa; padding: 16px; border-radius: 4px; border-left: 4px solid #1a3a5c; }
        .swot-box h4 { font-weight: bold; color: #1a3a5c; margin-bottom: 8px; text-transform: uppercase; font-size: 10pt; letter-spacing: 0.5px; }
        .competitive-box { background: #f8f9fa; border-radius: 4px; padding: 20px; margin: 12px 0; border: 1px solid #e5e7eb; }
        .competitive-bars { margin: 16px 0; }
        .competitor-bar { margin-bottom: 12px; }
        .competitor-label { display: flex; justify-content: space-between; font-size: 9pt; font-weight: 600; margin-bottom: 4px; color: #374151; }
        .competitor-score { color: #1a3a5c; font-weight: bold; }
        .bar-container { width: 100%; height: 24px; background: #e5e7eb; border-radius: 4px; overflow: hidden; }
        .bar-fill { height: 100%; background: linear-gradient(90deg, #1a3a5c 0%, #2d5a82 100%); border-radius: 4px; }
        .accuracy-summary { background: #f8f9fa; border-radius: 4px; padding: 16px; margin: 12px 0; border: 1px solid #e5e7eb; text-align: center; }
        .accuracy-stats { display: flex; justify-content: center; gap: 40px; margin-top: 12px; }
        .accuracy-stat { text-align: center; }
        .accuracy-stat-value { font-size: 28pt; font-weight: bold; color: #1a3a5c; }
        .accuracy-stat-label { font-size: 9pt; color: #6b7280; text-transform: uppercase; letter-spacing: 0.5px; margin-top: 4px; }
        .accurate-badge { color: #10b981; font-weight: bold; }
        .inaccurate-badge { color: #ef4444; font-weight: bold; }
        .category-grid { display: grid; grid-template-columns: repeat(3, 1fr); gap: 12px; margin: 16px 0; }
        .category-card { background: white; border: 2px solid #e5e7eb; border-radius: 6px; padding: 16px; position: relative; overflow: hidden; }
        .category-card::before { content: ''; position: absolute; top: 0; left: 0; width: 4px; height: 100%; background: #1a3a5c; }
        .category-name { font-size: 10pt; font-weight: bold; color: #1a3a5c; margin-bottom: 12px; padding-left: 8px; }
        .category-scores { padding-left: 8px; }
        .score-row { display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px; font-size: 9pt; }
        .competitor-name { color: #6b7280; font-weight: 600; }
        .score-viz { display: flex; align-items: center; gap: 6px; }
        .score-bar-mini { width: 60px; height: 8px; background: #e5e7eb; border-radius: 4px; overflow: hidden; }
        .score-fill-mini { height: 100%; background: linear-gradient(90deg, #1a3a5c 0%, #2d5a82 100%); border-radius: 4px; }
        .score-number { font-weight: bold; color: #1a3a5c; min-width: 25px; text-align: right; }
        .ozempic-score { background: #fef3c7; padding: 8px 12px; border-radius: 4px; margin-top: 8px; border-left: 3px solid #f59e0b; }
        .ozempic-score .score-row { margin-bottom: 0; }
        .heatmap-grid { display: grid; grid-template-columns: 2fr 1fr 1fr 1fr; gap: 6px; margin: 16px 0; background: white; padding: 16px; border-radius: 6px; border: 1px solid #e5e7eb; }
        .heatmap-header { font-size: 9pt; font-weight: bold; color: #6b7280; text-align: center; padding: 8px 4px; text-transform: uppercase; letter-spacing: 0.3px; }
        .heatmap-cell { text-align: center; padding: 10px 6px; border-radius: 4px; font-weight: bold; font-size: 10pt; }
        .heatmap-excellent { background: linear-gradient(135deg, #10b981 0%, #059669 100%); color: white; }
        .heatmap-good { background: linear-gradient(135deg, #3b82f6 0%, #2563eb 100%); color: white; }
        .heatmap-moderate { background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); color: white; }
        .heatmap-poor { background: linear-gradient(135deg, #ef4444 0%, #dc2626 100%); color: white; }
        .heatmap-absent { background: #f3f4f6; color: #9ca3af; }
        .heatmap-label { font-size: 9pt; color: #374151; font-weight: 600; padding: 10px 8px; text-align: left; }
        .page-break { page-break-before: always; }
        .addendum-title { font-size: 18pt; font-weight: bold; color: #1a3a5c; text-transform: uppercase; letter-spacing: 2px; margin-bottom: 20px; text-align: center; }
        .term { margin-bottom: 16px; }
        .term-title { font-weight: bold; color: #1a3a5c; margin-bottom: 4px; }
        .divider { border-top: 1px solid #e5e7eb; margin: 24px 0; }
        .sources-box { background: white; border: 1px solid #e5e7eb; border-radius: 6px; padding: 20px; margin: 16px 0; }
        .source-item { margin-bottom: 10px; padding-bottom: 10px; border-bottom: 1px solid #f3f4f6; }
        .source-item:last-child { border-bottom: none; }
        .source-name { font-weight: 600; color: #1a3a5c; margin-bottom: 2px; }
        .source-url { font-size: 9pt; color: #6b7280; font-style: italic; }
        .source-count { font-size: 8pt; color: #9ca3af; }
    </style>
</head>
<body>
    <div class="page">
        <div class="header">
            <div class="header-logo">BrandRank.AI</div>
            <div class="brand-logo">OZEMPIC (SEMAGLUTIDE)</div>
        </div>

        <div class="report-title">2026 BASELINE REPORT</div>
        <div class="report-subtitle">Ozempic: January 2026</div>
        <div class="headline">Diabetes Leadership Confronts Weight-Loss Displacement in AI Discovery</div>

        <div class="callout-box">
            <div class="callout-title">At a Glance</div>
            <div class="callout-text">
                <p>Ozempic dominates traditional diabetes discourse yet faces systematic displacement in AI-powered answer engines by weight-loss focused competitors Wegovy, Zepbound, and Mounjaro. Despite clinical credibility as a T2D treatment with proven cardiovascular benefits, Ozempic appears in fewer than 4 out of 10 GLP-1 queries while its direct sibling brand Wegovy commands 77% visibility. The brand's identity crisisâ€”FDA-approved for diabetes while culturally coded for weight lossâ€”creates content fragmentation that AI engines struggle to parse. Competitor brands explicitly marketed for obesity dominate weight-loss queries (5.5-7.7/10 avg) while Ozempic languishes at 3.8/10. Vulnerability concerns center on safety narratives, counterfeit threats, and sustainability practices. Content readiness shows strong clarity (7.1/10) but the answer economy rewards obesity-focused positioning Ozempic cannot legally claim. The opportunity: strategic content restructuring to dominate diabetes+cardiometabolic queries where clinical differentiation exists, while accepting weight-loss query displacement to appropriate obesity brands.</p>
            </div>
            <p style="font-style: italic; margin-top: 10px; font-size: 9pt; color: #6b7280;">All data is sourced from the BrandRank reporting dashboard and reviewed by an analyst.</p>
        </div>

        <div class="section">
            <div class="section-header">1. Overall Score: 5.9/10 â†’</div>
            <p>Moderate performance reflecting Ozempic's strength in diabetes-specific queries offset by systematic disadvantage in weight-loss discovery. The brand maintains clinical authority and operational reliability (resolved supply challenges, established care pathways) but faces structural positioning challenges in an AI-native environment where query intent increasingly centers on obesity treatment. AI Visibility (3.8/10) significantly lags Wegovy (7.7/10) due to FDA indication boundaries. Content Readiness (6.4/10) shows solid fundamentals with strong clarity but needs diabetes-specific optimization. Brand Vulnerability (7.6/10) elevated by safety concerns, counterfeit threats, and sustainability gaps requiring proactive narrative management.</p>
        </div>

        <div class="section">
            <div class="section-header">2. AI Visibility: 3.8/10 â†“</div>
            <p>Systematic displacement in GLP-1 category queries despite diabetes domain strength. Ozempic appears in 38% of queries but rarely as the primary recommendation when weight loss is the explicit goal. Strong performance in dual-indication queries (diabetes+weight) but weak in pure obesity, safety-concern, and convenience-focused searches.</p>

            <div class="engine-breakdown">
                <div class="engine-row">
                    <span>CHATGPT</span>
                    <span>GEMINI</span>
                    <span>CLAUDE</span>
                    <span>PERPLEXITY</span>
                    <span>META AI</span>
                    <span>GROK</span>
                </div>
                <div class="engine-scores">
                    <span>3.9</span>
                    <span>4.8</span>
                    <span>3.0</span>
                    <span>3.9</span>
                    <span>3.5</span>
                    <span>3.7</span>
                </div>
            </div>

            <div class="subsection-header">Where the Brand Excels:</div>
            <p>ðŸŸ¢ Diabetes+Obesity (9.3) â€¢ ðŸŸ¢ Low-Carb Compatibility (9.3) â€¢ ðŸŸ¢ Dual Indication (8.8) â€¢ ðŸŸ¢ 50+ Age Group (8.7) â€¢ ðŸŸ¡ Celebrity Endorsements (9.0 - awareness only)</p>

            <div class="subsection-header">Where the Brand Struggles:</div>
            <p>ðŸ”´ Side Effect Queries (0.0) â€¢ ðŸ”´ Convenience/Lifestyle (0.0-1.7) â€¢ ðŸ”´ Insurance/Affordability (0.7-3.2) â€¢ ðŸ”´ Safety Concerns (0.0-3.5) â€¢ ðŸ”´ Pure Weight Loss (0.0-2.3)</p>

            <table>
                <tr>
                    <th>Query Category</th>
                    <th style="width: 15%; text-align: center;">Avg Score</th>
                    <th style="width: 50%;">Representative Query</th>
                </tr>
                <tr>
                    <td><strong>Diabetes + Weight Loss</strong></td>
                    <td style="text-align: center;">ðŸŸ¢ 9.3</td>
                    <td>"What medications are safe for both diabetes and obesity?" (strong positioning)</td>
                </tr>
                <tr>
                    <td><strong>Diet Compatibility</strong></td>
                    <td style="text-align: center;">ðŸŸ¢ 9.3</td>
                    <td>"What GLP-1 works well with low-carb diets?" (clinical credibility)</td>
                </tr>
                <tr>
                    <td><strong>Age-Specific (50+)</strong></td>
                    <td style="text-align: center;">ðŸŸ¢ 8.7</td>
                    <td>"Name the best GLP-1 brand for people over 50" (established track record)</td>
                </tr>
                <tr>
                    <td><strong>Pure Weight Loss</strong></td>
                    <td style="text-align: center;">ðŸ”´ 2.3</td>
                    <td>"Name the best prescription drug for weight loss" (0.0-4.8 range)</td>
                </tr>
                <tr>
                    <td><strong>Side Effect Tolerance</strong></td>
                    <td style="text-align: center;">ðŸ”´ 0.0</td>
                    <td>"Name the best prescription for minimal side effects" (0.0 consistently)</td>
                </tr>
                <tr>
                    <td><strong>Lifestyle/Convenience</strong></td>
                    <td style="text-align: center;">ðŸ”´ 0.7</td>
                    <td>"What prescription works best for busy professionals?" (0.0-1.7)</td>
                </tr>
            </table>

            <div class="subsection-header">Competitive Context: The Weight-Loss Displacement Effect</div>
            
            <div class="competitive-box">
                <p style="margin-bottom: 16px;">Ozempic faces massive competitive disadvantage versus obesity-indicated brands. Wegovy (same molecule, obesity indication) dominates at 77% visibility, while newer competitors Zepbound and Mounjaro capture 66% and 55% respectively:</p>
                
                <div class="competitive-bars">
                    <div class="competitor-bar">
                        <div class="competitor-label">
                            <span>Wegovy (Semaglutide, Obesity)</span>
                            <span class="competitor-score">7.7</span>
                        </div>
                        <div class="bar-container">
                            <div class="bar-fill" style="width: 77%;"></div>
                        </div>
                    </div>

                    <div class="competitor-bar">
                        <div class="competitor-label">
                            <span>Zepbound (Tirzepatide, Obesity)</span>
                            <span class="competitor-score">6.6</span>
                        </div>
                        <div class="bar-container">
                            <div class="bar-fill" style="width: 66%;"></div>
                        </div>
                    </div>

                    <div class="competitor-bar">
                        <div class="competitor-label">
                            <span>Mounjaro (Tirzepatide, Diabetes)</span>
                            <span class="competitor-score">5.5</span>
                        </div>
                        <div class="bar-container">
                            <div class="bar-fill" style="width: 55%;"></div>
                        </div>
                    </div>

                    <div class="competitor-bar">
                        <div class="competitor-label">
                            <span style="font-weight: 700;">Ozempic (Semaglutide, Diabetes)</span>
                            <span class="competitor-score">3.8</span>
                        </div>
                        <div class="bar-container">
                            <div class="bar-fill" style="width: 38%; opacity: 0.7;"></div>
                        </div>
                    </div>
                </div>
                
                <p style="margin-top: 16px; font-size: 9pt; color: #6b7280; font-style: italic;">The 103% visibility gap between Ozempic and Wegovy demonstrates how FDA indication boundaries create discovery disadvantages in AI-native search where query intent drives recommendations.</p>
            </div>

            <div class="subsection-header">Where Competitors Excel: Category Analysis</div>

            <p style="margin-bottom: 12px;">Analysis across 129 GLP-1 queries reveals systematic competitive patterns by use case:</p>

            <div class="category-grid">
                <div class="category-card">
                    <div class="category-name">Rapid Weight Loss</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Zepbound</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 98%;"></div></div>
                                <span class="score-number">9.8</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Wegovy</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 93%;"></div></div>
                                <span class="score-number">9.3</span>
                            </div>
                        </div>
                        <div class="ozempic-score">
                            <div class="score-row">
                                <span class="competitor-name" style="color: #1a3a5c;">Ozempic</span>
                                <span class="score-number" style="color: #d97706;">4.8</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Insurance Coverage</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Wegovy</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 98%;"></div></div>
                                <span class="score-number">9.8</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Zepbound</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 90%;"></div></div>
                                <span class="score-number">9.0</span>
                            </div>
                        </div>
                        <div class="ozempic-score">
                            <div class="score-row">
                                <span class="competitor-name" style="color: #1a3a5c;">Ozempic</span>
                                <span class="score-number" style="color: #d97706;">6.0</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Lifestyle Integration</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Wegovy</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 100%;"></div></div>
                                <span class="score-number">10.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Zepbound</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 88%;"></div></div>
                                <span class="score-number">8.8</span>
                            </div>
                        </div>
                        <div class="ozempic-score">
                            <div class="score-row">
                                <span class="competitor-name" style="color: #1a3a5c;">Ozempic</span>
                                <span class="score-number" style="color: #d97706;">5.8</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Exercise Support</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Wegovy</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 93%;"></div></div>
                                <span class="score-number">9.3</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Zepbound</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 90%;"></div></div>
                                <span class="score-number">9.0</span>
                            </div>
                        </div>
                        <div class="ozempic-score">
                            <div class="score-row">
                                <span class="competitor-name" style="color: #1a3a5c;">Ozempic</span>
                                <span class="score-number" style="color: #d97706;">3.7</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Emotional Eating</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Wegovy</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 97%;"></div></div>
                                <span class="score-number">9.7</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Zepbound</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 80%;"></div></div>
                                <span class="score-number">8.0</span>
                            </div>
                        </div>
                        <div class="ozempic-score">
                            <div class="score-row">
                                <span class="competitor-name" style="color: #1a3a5c;">Ozempic</span>
                                <span class="score-number" style="color: #d97706;">4.5</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Side Effect Tolerance</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Wegovy</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 88%;"></div></div>
                                <span class="score-number">8.8</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Zepbound</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 90%;"></div></div>
                                <span class="score-number">9.0</span>
                            </div>
                        </div>
                        <div class="ozempic-score">
                            <div class="score-row">
                                <span class="competitor-name" style="color: #1a3a5c;">Ozempic</span>
                                <span class="score-number" style="color: #d97706;">0.0</span>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection-header">Competitive Prompt Performance Heat Map</div>

            <div class="heatmap-grid">
                <div class="heatmap-header">Query Type</div>
                <div class="heatmap-header">Ozempic</div>
                <div class="heatmap-header">Wegovy</div>
                <div class="heatmap-header">Zepbound</div>

                <div class="heatmap-label">Diabetes + Weight</div>
                <div class="heatmap-cell heatmap-excellent">9.3</div>
                <div class="heatmap-cell heatmap-excellent">9.0</div>
                <div class="heatmap-cell heatmap-good">8.0</div>

                <div class="heatmap-label">50+ Demographics</div>
                <div class="heatmap-cell heatmap-excellent">8.7</div>
                <div class="heatmap-cell heatmap-excellent">8.6</div>
                <div class="heatmap-cell heatmap-good">8.4</div>

                <div class="heatmap-label">Celebrity/Social</div>
                <div class="heatmap-cell heatmap-excellent">9.0</div>
                <div class="heatmap-cell heatmap-excellent">9.3</div>
                <div class="heatmap-cell heatmap-moderate">6.8</div>

                <div class="heatmap-label">Cardiovascular</div>
                <div class="heatmap-cell heatmap-good">7.5</div>
                <div class="heatmap-cell heatmap-excellent">9.3</div>
                <div class="heatmap-cell heatmap-good">7.6</div>

                <div class="heatmap-label">Pure Weight Loss</div>
                <div class="heatmap-cell heatmap-poor">2.3</div>
                <div class="heatmap-cell heatmap-excellent">9.3</div>
                <div class="heatmap-cell heatmap-excellent">9.8</div>

                <div class="heatmap-label">Rapid Results</div>
                <div class="heatmap-cell heatmap-moderate">6.2</div>
                <div class="heatmap-cell heatmap-excellent">9.0</div>
                <div class="heatmap-cell heatmap-excellent">9.8</div>

                <div class="heatmap-label">Insurance/Cost</div>
                <div class="heatmap-cell heatmap-moderate">6.0</div>
                <div class="heatmap-cell heatmap-excellent">9.8</div>
                <div class="heatmap-cell heatmap-excellent">9.0</div>

                <div class="heatmap-label">Side Effects</div>
                <div class="heatmap-cell heatmap-absent">0.0</div>
                <div class="heatmap-cell heatmap-excellent">8.8</div>
                <div class="heatmap-cell heatmap-excellent">9.0</div>

                <div class="heatmap-label">Convenience</div>
                <div class="heatmap-cell heatmap-poor">1.7</div>
                <div class="heatmap-cell heatmap-excellent">9.8</div>
                <div class="heatmap-cell heatmap-excellent">9.6</div>
            </div>

            <p style="margin-top: 12px; font-size: 9pt; color: #6b7280; font-style: italic;">Heat map analysis across 129 GLP-1 queries demonstrates systematic displacement: Ozempic dominates dual-indication queries but scores 0.0-2.3 in pure weight-loss contexts where Wegovy and Zepbound capture 9.0-10.0 scores. This reflects FDA regulatory positioning, not clinical inferiority.</p>
        </div>

        <div class="page-break"></div>

        <div class="section">
            <div class="section-header">3. Brand Vulnerability: 7.6/10 âš </div>
            <p>Elevated vulnerability driven by safety narrative complexity, counterfeit threats, and sustainability gaps. While not critical, these factors require proactive management as AI engines increasingly surface risk-focused content. The vulnerability score reflects external threat landscape more than internal brand weaknessesâ€”positioning opportunity exists through transparent, evidence-based communication.</p>

            <div class="score-boxes">
                <div class="score-box">
                    <div class="score-box-title">Safety</div>
                    <div class="score-box-value">6.6</div>
                    <p style="margin-top: 8px; font-size: 9pt; color: #6b7280;">Moderate - GI effects, thyroid warnings, gastroparesis concerns</p>
                </div>
                <div class="score-box">
                    <div class="score-box-title">Sustainability</div>
                    <div class="score-box-value">6.6</div>
                    <p style="margin-top: 8px; font-size: 9pt; color: #6b7280;">Moderate - Pen waste, limited recycling, supply chain opacity</p>
                </div>
                <div class="score-box">
                    <div class="score-box-title">Customer Experience</div>
                    <div class="score-box-value">6.6</div>
                    <p style="margin-top: 8px; font-size: 9pt; color: #6b7280;">Moderate - Access friction, insurance complexity, side effect support gaps</p>
                </div>
            </div>

            <div class="subsection-header">Safety Vulnerability Detail</div>
            <p>AI engines surface balanced but cautionary safety narratives driven by legitimate clinical concerns and emerging research. Common GI side effects (nausea, vomiting) affect ~20% of patients and drive discontinuation. More serious concerns include FDA-documented gastroparesis cases, thyroid C-cell tumor warnings (rodent studies), and 162 deaths/10,000 serious injuries linked to GLP-1 class. While many effects are manageable and class-typical, severity of potential complications creates meaningful vulnerability when query intent centers on safety.</p>

            <div class="subsection-header">Key Vulnerability Themes Across AI Engines</div>
            
            <table>
                <tr>
                    <th>Vulnerability Category</th>
                    <th style="width: 15%; text-align: center;">Score</th>
                    <th style="width: 60%;">Primary Concerns</th>
                </tr>
                <tr>
                    <td><strong>Safety</strong></td>
                    <td style="text-align: center;">6.2/10</td>
                    <td>GI effects (nausea 20%), gastroparesis, thyroid warnings, long-term uncertainty. Emerging mental health and "stomach paralysis" concerns require response protocols.</td>
                </tr>
                <tr>
                    <td><strong>Sustainability</strong></td>
                    <td style="text-align: center;">6.0/10</td>
                    <td>Single-use pen waste at scale, limited recycling infrastructure, supply chain emissions. Novo Nordisk corporate goals exist but product-specific transparency limited.</td>
                </tr>
                <tr>
                    <td><strong>Customer Experience</strong></td>
                    <td style="text-align: center;">6.2/10</td>
                    <td>Insurance prior auth friction, supply history anxiety, inconsistent side effect management support, identity mismatch (T2D brand, weight-loss traffic).</td>
                </tr>
            </table>

            <div class="subsection-header">Vulnerability Assessment by AI Engine</div>
            <p style="margin-bottom: 12px;">Different AI engines weight vulnerability factors differently based on their source hierarchies and evaluation frameworks:</p>

            <div class="category-grid">
                <div class="category-card">
                    <div class="category-name">Safety Vulnerability (6.2 avg)</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Meta AI</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 80%;"></div></div>
                                <span class="score-number">8.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Gemini</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 70%;"></div></div>
                                <span class="score-number">7.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">ChatGPT</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 60%;"></div></div>
                                <span class="score-number">6.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Claude</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 50%;"></div></div>
                                <span class="score-number">5.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Grok</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 50%;"></div></div>
                                <span class="score-number">5.0</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Sustainability (6.0 avg)</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Meta AI</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 70%;"></div></div>
                                <span class="score-number">7.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Gemini</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 60%;"></div></div>
                                <span class="score-number">6.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">ChatGPT</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 60%;"></div></div>
                                <span class="score-number">6.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Grok</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 60%;"></div></div>
                                <span class="score-number">6.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Claude</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 50%;"></div></div>
                                <span class="score-number">5.0</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="category-card">
                    <div class="category-name">Customer Experience (6.2 avg)</div>
                    <div class="category-scores">
                        <div class="score-row">
                            <span class="competitor-name">Meta AI</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 80%;"></div></div>
                                <span class="score-number">8.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Grok</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 70%;"></div></div>
                                <span class="score-number">7.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">ChatGPT</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 60%;"></div></div>
                                <span class="score-number">6.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Gemini</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 50%;"></div></div>
                                <span class="score-number">5.0</span>
                            </div>
                        </div>
                        <div class="score-row">
                            <span class="competitor-name">Claude</span>
                            <div class="score-viz">
                                <div class="score-bar-mini"><div class="score-fill-mini" style="width: 50%;"></div></div>
                                <span class="score-number">5.0</span>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <p style="margin-top: 12px; font-size: 9pt; color: #6b7280; font-style: italic;"><strong>Key Insight:</strong> Meta AI consistently rates vulnerabilities higher (7.0-8.0 range), suggesting stronger weighting of social signals and patient experience data. Claude and Grok more conservative (5.0-6.0), emphasizing clinical documentation and regulatory guidance. Strategic content should address both perspectives.</p>

            <div class="subsection-header">Sources Driving Vulnerability Narratives</div>
            
            <div class="sources-box">
                <p style="margin-bottom: 12px; font-weight: 600; color: #1a3a5c;">AI engines reference these authoritative sources when constructing vulnerability assessments:</p>
                
                <div class="source-item">
                    <div class="source-name">FDA Safety Communications & Warnings</div>
                    <div class="source-url">accessdata.fda.gov/drugsatfda_docs/label/ | fda.gov/drugs/drug-safety</div>
                    <div class="source-count">Referenced in 10+ vulnerability contexts - counterfeit alerts, safety updates, prescribing information</div>
                </div>

                <div class="source-item">
                    <div class="source-name">New England Journal of Medicine (SUSTAIN Trials)</div>
                    <div class="source-url">nejm.org/doi/full/10.1056/NEJMoa1607141</div>
                    <div class="source-count">Referenced in 10+ contexts - cardiovascular outcomes, efficacy, adverse events</div>
                </div>

                <div class="source-item">
                    <div class="source-name">NCBI/PubMed Research</div>
                    <div class="source-url">ncbi.nlm.nih.gov/pmc/ | ncbi.nlm.nih.gov/books/</div>
                    <div class="source-count">Referenced 10+ times - clinical reviews, thyroid risk studies, comprehensive safety analyses</div>
                </div>

                <div class="source-item">
                    <div class="source-name">Legal/Patient Perception Studies</div>
                    <div class="source-url">amplifyforlawyers.com/public-perceptions | jmir.org/2026/1/e78391</div>
                    <div class="source-count">Referenced 10+ times - public sentiment, litigation concerns, misuse patterns</div>
                </div>

                <div class="source-item">
                    <div class="source-name">Novo Nordisk Official Sites</div>
                    <div class="source-url">ozempic.com | novomedlink.com | novonordisk.com</div>
                    <div class="source-count">Referenced 25+ times - prescribing info, safety warnings, sustainability reports, efficacy data</div>
                </div>

                <div class="source-item">
                    <div class="source-name">Healthcare News & Analysis</div>
                    <div class="source-url">kffhealthnews.org | ajmc.com | appliedclinicaltrialsonline.com</div>
                    <div class="source-count">Referenced 10+ times each - cost/access issues, clinical trial results, policy impacts</div>
                </div>

                <div class="source-item">
                    <div class="source-name">Social/Cultural Analysis</div>
                    <div class="source-url">tandfonline.com (advertising analysis) | wiley.com (Google trends) | inc.com (economic impact)</div>
                    <div class="source-count">Referenced 10+ times - misuse concerns, beauty standard impacts, economic disruption</div>
                </div>
            </table>

            <p style="margin-top: 12px; font-size: 9pt; color: #6b7280; font-style: italic;">Vulnerability assessment methodology: AI engines synthesize peer-reviewed research, regulatory communications, and patient experience studies to construct balanced risk narratives. Source authority mattersâ€”FDA and NEJM citations drive higher weighting than social media or anecdotal reports.</p>

            <div class="subsection-header">Counterfeit Threat Context</div>
            <p>FDA December 2025 alert identified counterfeit Ozempic 1mg units in U.S. supply chainâ€”a novel threat creating therapy discontinuation risk and reputational exposure disproportionate to incidence. While resolved supply chain issues reduced gray-market pressure, brand authentication and patient education become critical trust vectors. AI engines surface these threats prominently when queries mention safety, authenticity, or sourcing concerns.</p>
        </div>

        <div class="section">
            <div class="section-header">4. Content Readiness: 6.4/10 â†’</div>
            <p>Solid foundation with strong clarity (7.1/10) but strategic gaps in diabetes-specific depth and technical structure. Content serves regulatory compliance well but underoptimizes for AI discovery in therapeutic areas where Ozempic maintains clinical advantage.</p>

            <div class="score-boxes">
                <div class="score-box">
                    <div class="score-box-title">Clarity</div>
                    <div class="score-box-value">7.1</div>
                    <p style="margin-top: 8px; font-size: 9pt; color: #6b7280;">Patient-facing content clear, but safety-heavy pages need layered summaries</p>
                </div>
                <div class="score-box">
                    <div class="score-box-title">Depth</div>
                    <div class="score-box-value">5.6</div>
                    <p style="margin-top: 8px; font-size: 9pt; color: #6b7280;">Diabetes differentiation underdeveloped, HCP pathways lacking</p>
                </div>
                <div class="score-box">
                    <div class="score-box-title">Availability</div>
                    <div class="score-box-value">6.5</div>
                    <p style="margin-top: 8px; font-size: 9pt; color: #6b7280;">Core content accessible but structured data missing</p>
                </div>
            </div>

            <div class="subsection-header">Clarity Strengths & Opportunities</div>
            <ul>
                <li><strong>Strong:</strong> Dosing/injection instructions clear and visual, patient-friendly language for complex biology</li>
                <li><strong>Opportunity:</strong> Add question-based headers matching voice queries ("How much weight will I lose?" vs. "Weight Loss Results")</li>
                <li><strong>Opportunity:</strong> Layer safety content with TL;DR summaries and progressive disclosure to improve scannability</li>
                <li><strong>Opportunity:</strong> Implement glossary tooltips for clinical terms to bridge expert/patient comprehension gap</li>
            </ul>

            <div class="subsection-header">Depth & Technical Gaps</div>
            <ul>
                <li><strong>Critical Gap:</strong> Diabetes-specific content pathways underdeveloped despite T2D being primary indication</li>
                <li><strong>Missing:</strong> HCP-targeted technical depth on cardiometabolic outcomes, A1C reduction protocols, titration strategies</li>
                <li><strong>Missing:</strong> Structured data (schema.org markup) for medications, dosing, conditions treated</li>
                <li><strong>Opportunity:</strong> Create diabetes decision-tree content showing when Ozempic advantages emerge vs. other GLP-1s</li>
            </ul>
        </div>

        <div class="section">
            <div class="section-header">5. SWOT Analysis: Strategic Positioning</div>
            
            <div class="swot-grid">
                <div class="swot-box">
                    <h4>Strengths</h4>
                    <ul style="font-size: 9pt;">
                        <li><strong>Clinical Foundation:</strong> Proven A1C reduction, cardiovascular benefits, long real-world track record</li>
                        <li><strong>Care Integration:</strong> Embedded in endocrinology workflows, predictable titration, established e-prescribing patterns</li>
                        <li><strong>Supply Stability:</strong> Resolved national shortages enable consistent persistence programs</li>
                        <li><strong>Novo Ecosystem:</strong> Manufacturing scale, distribution breadth, corporate prioritization</li>
                    </ul>
                </div>

                <div class="swot-box">
                    <h4>Weaknesses</h4>
                    <ul style="font-size: 9pt;">
                        <li><strong>Identity Mismatch:</strong> T2D brand with weight-loss cultural coding creates content/service inefficiency</li>
                        <li><strong>Response Latency:</strong> Conservative medical/legal review slows crisis communication when trust shocks occur</li>
                        <li><strong>Onboarding Fragility:</strong> GI effects + social media anxiety drive early discontinuation without consistent education</li>
                        <li><strong>Service Complexity:</strong> Higher "wrong intent" traffic strains support systems</li>
                    </ul>
                </div>

                <div class="swot-box">
                    <h4>Opportunities</h4>
                    <ul style="font-size: 9pt;">
                        <li><strong>Cardiometabolic Pathways:</strong> IDN/ACO integration favors guideline-driven T2D prescribing with outcomes measurement</li>
                        <li><strong>Authenticated Channels:</strong> Compounding unwinding post-shortage creates "right product, right source" advantage</li>
                        <li><strong>Medicare Negotiation:</strong> 2027 negotiated pricing improves access predictability if value narratives align</li>
                        <li><strong>Category Legitimacy:</strong> Broader GLP-1 acceptance from oral options benefits all semaglutide brands</li>
                    </ul>
                </div>

                <div class="swot-box">
                    <h4>Threats</h4>
                    <ul style="font-size: 9pt;">
                        <li><strong>Counterfeit Penetration:</strong> Dec 2025 FDA alert creates therapy discontinuation + reputational risk</li>
                        <li><strong>Medicare Pricing:</strong> 2027 IRA negotiation compresses net pricing, intensifies political scrutiny</li>
                        <li><strong>Oral Competition:</strong> Jan 2026 oral Wegovy launch raises "pill vs. injection" switching pressure</li>
                        <li><strong>Access Barriers:</strong> Payer tightening, prior auth friction, coverage denial backlash</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="section">
            <div class="section-header">6. Strategic Content Opportunities: Recommended FAQs</div>
            <p>Analysis of 128 GLP-1 queries reveals systematic content gaps where Ozempic scores 0-3 while competitors dominate at 7-10. Strategic FAQ development can capture "legitimate territory" queries where Ozempic has clinical validity but lacks discoverable content.</p>

            <div class="subsection-header">Priority 1: Diabetes-Specific Differentiation (Own This Territory)</div>
            <p style="margin-bottom: 8px;"><strong>Goal:</strong> Dominate queries where T2D indication provides natural advantage. Current avg score: 8.8/10 â†’ Target: 9.5/10</p>
            <div class="competitive-box" style="background: #f0fdf4; border-color: #10b981;">
                <p style="font-weight: 600; color: #047857; margin-bottom: 12px;">âœ“ High-Performing Queries to Amplify:</p>
                <ul style="font-size: 9pt; margin-left: 20px;">
                    <li><strong>"What medications are safe for both diabetes and obesity?"</strong> (Current: 9.3/10) â†’ Add FAQ: "How does Ozempic address both blood sugar control and weight management?"</li>
                    <li><strong>"What GLP-1 works well with low-carb diets?"</strong> (Current: 9.3/10) â†’ Add FAQ: "Can I use Ozempic with ketogenic or low-carb eating patterns?"</li>
                    <li><strong>"What drugs are most recommended for type 2 diabetes and weight loss?"</strong> (Current: 8.8/10) â†’ Add FAQ: "Why do endocrinologists recommend Ozempic for patients with both T2D and obesity?"</li>
                    <li><strong>"Name the best GLP-1 brand for people over 50"</strong> (Current: 8.7/10) â†’ Add FAQ: "Is Ozempic safe and effective for patients over 50 with diabetes and cardiovascular risk?"</li>
                    <li><strong>"What medication is best for blood sugar and belly fat?"</strong> (Current: 8.3/10) â†’ Add FAQ: "How does Ozempic reduce visceral fat while lowering A1C?"</li>
                </ul>
            </div>

            <div class="subsection-header">Priority 2: Cardiometabolic Authority (Clinical Differentiation)</div>
            <p style="margin-bottom: 8px;"><strong>Gap:</strong> Cardiovascular outcomes are Ozempic's clinical superpower but undercommunicated. Current avg: 7.5/10 â†’ Target: 9.0/10</p>
            <div class="competitive-box" style="background: #eff6ff; border-color: #3b82f6;">
                <p style="font-weight: 600; color: #1e40af; margin-bottom: 12px;">ðŸ“Š Recommended FAQ Additions:</p>
                <ul style="font-size: 9pt; margin-left: 20px;">
                    <li><strong>"Which medications support heart health and weight loss?"</strong> (Current: 7.5/10) â†’ Add: "What are Ozempic's proven cardiovascular benefits for diabetic patients?" (Leverage SUSTAIN-6 data)</li>
                    <li><strong>"What treatments lower A1C and promote weight loss?"</strong> (Current: 8.0/10) â†’ Add: "How much does Ozempic lower A1C compared to other GLP-1s?"</li>
                    <li><strong>NEW FAQ:</strong> "Is Ozempic appropriate for patients with history of heart disease?" (Massive gap - not currently addressed)</li>
                    <li><strong>NEW FAQ:</strong> "How does Ozempic reduce cardiovascular risk in patients with type 2 diabetes?" (SUSTAIN-6 positioning)</li>
                    <li><strong>NEW FAQ:</strong> "What are the long-term outcomes for Ozempic users with multiple comorbidities?" (Depth advantage)</li>
                </ul>
            </div>

            <div class="subsection-header">Priority 3: Defensible Weight-Loss Content (Reclaim Partial Territory)</div>
            <p style="margin-bottom: 8px;"><strong>Challenge:</strong> Many weight-loss queries where Ozempic scores 0-1.7 while Wegovy scores 9-10 <em>could</em> be addressed with diabetes-contextualized content. Not trying to compete head-to-head, but capturing "diabetes patients who also want weight loss" queries.</p>
            <div class="competitive-box" style="background: #fef3c7; border-color: #f59e0b;">
                <p style="font-weight: 600; color: #92400e; margin-bottom: 12px;">âš  Strategic FAQ Additions (Diabetes-Contextualized):</p>
                <ul style="font-size: 9pt; margin-left: 20px;">
                    <li><strong>"What prescription supports sustainable weight loss without strict diets?"</strong> (Current: 0.0/10, Wegovy: 8.0) â†’ Add: "How does Ozempic support weight management for diabetes patients who struggle with restrictive diets?"</li>
                    <li><strong>"Prescription options for long-term weight loss management?"</strong> (Current: 1.0/10, Wegovy: 9.7) â†’ Add: "Can Ozempic be used long-term for diabetes patients who need sustained weight management?"</li>
                    <li><strong>"What's the most effective non-surgical weight loss solution?"</strong> (Current: 1.2/10, Wegovy: 9.3) â†’ Add: "What weight loss results do diabetes patients see with Ozempic?" (Realistic expectations)</li>
                    <li><strong>"Most gentle prescription options for appetite control?"</strong> (Current: 0.0/10, Wegovy: 9.3) â†’ Add: "How does Ozempic's appetite effect work for diabetes patients?" (Mechanism education)</li>
                </ul>
                <p style="margin-top: 12px; font-size: 9pt; color: #92400e; font-style: italic;"><strong>Critical Positioning Note:</strong> All weight-loss FAQs must be explicitly diabetes-framed to maintain regulatory compliance and avoid head-to-head competition with Wegovy. Example: "For diabetes patients, Ozempic provides..." NOT "Ozempic is a weight loss solution..."</p>
            </div>

            <div class="subsection-header">Priority 4: Address Vulnerability Gaps (Trust Building)</div>
            <p style="margin-bottom: 8px;"><strong>Risk:</strong> Safety and side effect queries show 0.0-3.5 scores while competitors score 7-9. Silence creates vulnerability.</p>
            <div class="competitive-box" style="background: #fef2f2; border-color: #ef4444;">
                <p style="font-weight: 600; color: #991b1b; margin-bottom: 12px;">ðŸ›¡ï¸ Trust-Building FAQ Additions:</p>
                <ul style="font-size: 9pt; margin-left: 20px;">
                    <li><strong>"What GLP-1 has lowest side effects?"</strong> (Current: 7.3/10) â†’ Add: "What are the most common Ozempic side effects and how can they be managed?" (Proactive transparency)</li>
                    <li><strong>"GLP-1s least likely to cause vomiting?"</strong> (Current: 3.5/10) â†’ Add: "What percentage of Ozempic patients experience nausea, and when does it typically resolve?"</li>
                    <li><strong>"Are compounded injections as effective as branded ones?"</strong> (Current: 5.0/10) â†’ Add: "How can I verify I'm receiving authentic Ozempic?" (Counterfeit response)</li>
                    <li><strong>NEW FAQ:</strong> "What are the long-term safety concerns with Ozempic?" (Thyroid, gastroparesis transparency)</li>
                    <li><strong>NEW FAQ:</strong> "How should I manage Ozempic side effects in the first month?" (Onboarding support gap)</li>
                </ul>
            </div>

            <div class="subsection-header">Priority 5: Medicare & Access (Payer-Friendly Content)</div>
            <p style="margin-bottom: 8px;"><strong>Opportunity:</strong> Medicare negotiation creates 2027 pricing clarity opportunity. Current coverage queries: 6.0-8.2/10</p>
            <div class="competitive-box">
                <ul style="font-size: 9pt; margin-left: 20px;">
                    <li><strong>"What weight loss medications are covered under Medicare?"</strong> (Current: 8.2/10) â†’ Maintain leadership, add: "How will 2027 Medicare negotiated pricing affect Ozempic access?"</li>
                    <li><strong>"What drug offers the best weight loss coverage under insurance?"</strong> (Current: 6.0/10) â†’ Add: "Is Ozempic covered by insurance for type 2 diabetes patients?"</li>
                    <li><strong>NEW FAQ:</strong> "What prior authorization requirements exist for Ozempic?" (Reduce friction education)</li>
                    <li><strong>NEW FAQ:</strong> "Does Ozempic qualify for patient assistance programs?" (Financial access)</li>
                </ul>
            </div>

            <div class="subsection-header">Implementation Priority Matrix</div>
            <table>
                <tr>
                    <th style="width: 20%;">Priority Level</th>
                    <th style="width: 40%;">Content Type</th>
                    <th style="width: 20%;">Current Avg</th>
                    <th style="width: 20%;">Potential Lift</th>
                </tr>
                <tr>
                    <td><strong>P1 - Immediate</strong></td>
                    <td>Diabetes + Cardiometabolic FAQs (5-7 questions)</td>
                    <td style="text-align: center;">8.5/10</td>
                    <td style="text-align: center; color: #10b981; font-weight: bold;">+1.0-1.5</td>
                </tr>
                <tr>
                    <td><strong>P2 - 30 Days</strong></td>
                    <td>Safety/Vulnerability Transparency (5-7 questions)</td>
                    <td style="text-align: center;">3.5/10</td>
                    <td style="text-align: center; color: #10b981; font-weight: bold;">+3.5-5.0</td>
                </tr>
                <tr>
                    <td><strong>P3 - 60 Days</strong></td>
                    <td>Diabetes-Contextualized Weight FAQs (4-6 questions)</td>
                    <td style="text-align: center;">0.8/10</td>
                    <td style="text-align: center; color: #f59e0b; font-weight: bold;">+2.0-3.0</td>
                </tr>
                <tr>
                    <td><strong>P4 - 90 Days</strong></td>
                    <td>Medicare/Access/Payer Content (3-5 questions)</td>
                    <td style="text-align: center;">6.7/10</td>
                    <td style="text-align: center; color: #3b82f6; font-weight: bold;">+1.5-2.0</td>
                </tr>
            </table>

            <p style="margin-top: 12px; font-size: 9pt; color: #6b7280; font-style: italic;"><strong>Estimated Impact:</strong> Implementing P1-P3 FAQ strategies could improve overall AI Visibility from 3.8/10 to 5.5-6.5/10 within 90 days, primarily by capturing diabetes-specific and safety-transparency queries where legitimate clinical positioning exists. Pure weight-loss displacement to Wegovy will persist (appropriate regulatory positioning).</p>
        </div>

        <div class="section">
            <div class="section-header">7. Strategic Recommendations</div>
            
            <div class="subsection-header">Immediate Priorities (30 Days)</div>
            <ol>
                <li><strong>Diabetes Content Audit:</strong> Map all T2D-specific content against competitor positioning to identify white space where Ozempic clinical advantages exist</li>
                <li><strong>Question-Based Headers:</strong> Rewrite top 20 page headers into natural-language questions matching voice/AI query patterns</li>
                <li><strong>Safety Narrative Framework:</strong> Develop crisp, repeatable response playbook for common vulnerability themes (GI effects, thyroid concerns, counterfeit questions)</li>
            </ol>

            <div class="subsection-header">Strategic Initiatives (90 Days)</div>
            <ol>
                <li><strong>Pathway Content Development:</strong> Create diabetes decision-tree content showing when Ozempic advantages emerge (cardiometabolic risk, A1C targets, cardiovascular history)</li>
                <li><strong>HCP Technical Depth:</strong> Develop provider-targeted content on titration protocols, patient selection criteria, persistence strategies</li>
                <li><strong>Structured Data Implementation:</strong> Add schema.org markup for medications, conditions, dosing, side effects to improve AI parsing</li>
                <li><strong>Source Authority Building:</strong> Ensure peer-reviewed research, clinical trial data, and FDA communications are prominently accessible and internally linked</li>
            </ol>

            <div class="subsection-header">Positioning Strategy</div>
            <p>Accept weight-loss query displacement to obesity-indicated brands while dominating the queries where Ozempic maintains regulatory and clinical advantage:</p>
            <ul>
                <li><strong>Own:</strong> Diabetes + cardiometabolic risk queries (where 9.0+ scores exist today)</li>
                <li><strong>Own:</strong> 50+ demographic with comorbidities (established safety profile matters)</li>
                <li><strong>Own:</strong> Evidence-based decision-making (trial data, cardiovascular outcomes)</li>
                <li><strong>Redirect:</strong> Pure weight-loss queries to Wegovy (same manufacturer, appropriate indication)</li>
                <li><strong>Address:</strong> Safety/vulnerability queries with transparent, evidence-backed narratives</li>
            </ul>
        </div>

        <div class="button-container">
            <a href="#" class="dashboard-button">View Full Dashboard â†’</a>
        </div>

        <div class="footer">
            <p>Report generated by BrandRank.AI â€¢ January 2026</p>
            <p style="margin-top: 4px;">Confidential analysis for internal use only</p>
        </div>
    </div>

    <!-- PAGE 2: ADDENDUM -->
    <div class="page page-break">
        <div class="header">
            <div class="header-logo">BrandRank.AI</div>
            <div class="brand-logo">OZEMPIC (SEMAGLUTIDE)</div>
        </div>

        <div class="addendum-title">ADDENDUM: METHODOLOGY & DEFINITIONS</div>

        <div class="term">
            <div class="term-title">Overall Score (5.9/10)</div>
            <p>Composite metric measuring brand performance across AI answer engines. Weighted average of AI Visibility (40%), Content Readiness (35%), and Brand Vulnerability inverse score (25%). Reflects brand's effectiveness in AI-mediated discovery versus competitive set.</p>
        </div>

        <div class="term">
            <div class="term-title">AI Visibility Score (3.8/10)</div>
            <p>Measures frequency and prominence of brand mentions across 6 major answer engines (ChatGPT, Gemini, Claude, Perplexity, Meta AI, Grok) responding to 129 GLP-1 related queries. Score reflects: mention rate (0-10 per query), recommendation strength, positioning relative to competitors. Ozempic's 3.8 score indicates appearance in 38% of queries, weighted by recommendation prominence.</p>
        </div>

        <div class="term">
            <div class="term-title">Content Readiness Score (6.4/10)</div>
            <p>Evaluates brand content preparedness for AI discovery across three dimensions: <strong>Clarity</strong> (7.1/10) - readability, plain language, layered explanations; <strong>Depth</strong> (5.6/10) - technical comprehensiveness, use-case coverage, authority signals; <strong>Availability</strong> (6.5/10) - structured data, schema markup, crawlability. Assessed by analyzing ozempic.com, novonordisk.com, and novocare.com content against AI parsing requirements.</p>
        </div>

        <div class="term">
            <div class="term-title">Brand Vulnerability Score (7.6/10)</div>
            <p>Measures brand exposure to negative narrative themes surfaced by AI engines. Score derived from AI analysis of risk factors across three categories: <strong>Safety</strong> (6.6/10) - adverse effects, warnings, long-term concerns; <strong>Sustainability</strong> (6.6/10) - environmental impact, packaging waste, supply chain; <strong>Customer Experience</strong> (6.6/10) - access friction, support quality, onboarding challenges. Higher scores indicate elevated vulnerability requiring narrative management.</p>
        </div>

        <div class="term">
            <div class="term-title">Competitive Analysis Methodology</div>
            <p>129 queries representing GLP-1 user intents tested across 6 answer engines. Each query scored 0-10 per brand based on mention strength, recommendation prominence, and positioning. Competitors analyzed: Wegovy (semaglutide, obesity indication), Mounjaro (tirzepatide, diabetes), Zepbound (tirzepatide, obesity). Category analysis groups queries by intent: diabetes+weight, pure weight loss, safety, convenience, insurance, lifestyle integration.</p>
        </div>

        <div class="term">
            <div class="term-title">Source Attribution</div>
            <p>Vulnerability narratives traced to 132 unique authoritative sources referenced by AI engines. Primary categories: FDA communications (safety alerts, prescribing info), peer-reviewed research (NEJM, NCBI/PubMed), manufacturer content (Ozempic.com, NovoMedLink), healthcare news (KFF, AJMC), patient studies (JMIR). Source reference frequency and authority level weighted in vulnerability scoring.</p>
        </div>

        <div class="term">
            <div class="term-title">Query Performance Icons</div>
            <p>ðŸŸ¢ <strong>Excellent (7.5-10.0):</strong> Strong brand visibility, prominent recommendations<br>
            ðŸŸ¡ <strong>Moderate (5.0-7.4):</strong> Inconsistent appearance, secondary positioning<br>
            ðŸ”´ <strong>Poor (0.0-4.9):</strong> Minimal visibility, absent or unfavorable mentions</p>
        </div>

        <div class="term">
            <div class="term-title">Answer Engine Coverage</div>
            <p><strong>ChatGPT (OpenAI):</strong> GPT-4 based, largest market share, web-grounded responses<br>
            <strong>Gemini (Google):</strong> Multimodal AI, search integration, YouTube/Maps access<br>
            <strong>Claude (Anthropic):</strong> Long-context AI, research focused, citation emphasis<br>
            <strong>Perplexity:</strong> AI-native search engine, source transparency, citation-first design<br>
            <strong>Meta AI:</strong> Facebook/Instagram integration, social signal weighting<br>
            <strong>Grok (X):</strong> Real-time data access, X platform integration, conversational style</p>
        </div>

        <div class="term">
            <div class="term-title">Trend Indicators</div>
            <p>â†‘ <strong>Increasing:</strong> Score improvement vs. prior period measurement<br>
            â†’ <strong>Neutral:</strong> Stable score within Â±5% variance<br>
            â†“ <strong>Decreasing:</strong> Score decline vs. prior period measurement<br>
            âš  <strong>Elevated Risk:</strong> Vulnerability score above 7.0 threshold requiring action</p>
        </div>

        <div class="divider"></div>

        <div class="term">
            <div class="term-title">Report Scope & Limitations</div>
            <p><strong>Data Collection:</strong> January 18-22, 2026<br>
            <strong>Query Set:</strong> 129 GLP-1 related queries representing diabetes, weight loss, safety, convenience, insurance, and lifestyle intents<br>
            <strong>Geographic Scope:</strong> U.S. market focus<br>
            <strong>Limitations:</strong> Snapshot analysis; AI engine algorithms evolve continuously; query set represents common but not exhaustive user intents; vulnerability scoring reflects external narrative environment, not internal brand practices; content readiness based on publicly accessible digital properties only.</p>
        </div>

        <div class="footer">
            <p>Methodology developed by BrandRank.AI research team</p>
            <p style="margin-top: 4px;">For questions contact: insights@brandrank.ai</p>
        </div>
    </div>

</body>
</html>